Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 22 studies | 31% ± 14% | |
| astrocyte | 12 studies | 34% ± 15% | |
| microglial cell | 11 studies | 34% ± 12% | |
| oligodendrocyte | 11 studies | 35% ± 12% | |
| GABAergic neuron | 10 studies | 40% ± 22% | |
| glutamatergic neuron | 10 studies | 46% ± 23% | |
| macrophage | 10 studies | 33% ± 14% | |
| oligodendrocyte precursor cell | 10 studies | 38% ± 15% | |
| fibroblast | 10 studies | 29% ± 11% | |
| adipocyte | 9 studies | 30% ± 7% | |
| epithelial cell | 8 studies | 32% ± 15% | |
| pericyte | 7 studies | 27% ± 11% | |
| interneuron | 6 studies | 48% ± 23% | |
| myeloid cell | 6 studies | 24% ± 7% | |
| T cell | 6 studies | 22% ± 6% | |
| endothelial cell of lymphatic vessel | 6 studies | 33% ± 11% | |
| type I pneumocyte | 6 studies | 28% ± 11% | |
| type II pneumocyte | 6 studies | 23% ± 8% | |
| smooth muscle cell | 6 studies | 24% ± 6% | |
| neuron | 5 studies | 45% ± 18% | |
| dendritic cell | 5 studies | 25% ± 4% | |
| ciliated cell | 5 studies | 26% ± 7% | |
| granule cell | 4 studies | 32% ± 6% | |
| cardiac muscle cell | 4 studies | 26% ± 2% | |
| lymphocyte | 4 studies | 32% ± 13% | |
| amacrine cell | 4 studies | 23% ± 6% | |
| retinal cone cell | 4 studies | 28% ± 10% | |
| retinal rod cell | 4 studies | 34% ± 8% | |
| club cell | 4 studies | 28% ± 9% | |
| monocyte | 4 studies | 30% ± 7% | |
| basal cell | 4 studies | 37% ± 21% | |
| GABAergic interneuron | 3 studies | 35% ± 6% | |
| retinal ganglion cell | 3 studies | 27% ± 8% | |
| plasma cell | 3 studies | 28% ± 3% | |
| CD4-positive, alpha-beta T cell | 3 studies | 20% ± 1% | |
| mesothelial cell | 3 studies | 27% ± 6% | |
| vein endothelial cell | 3 studies | 34% ± 20% | |
| Mueller cell | 3 studies | 24% ± 6% | |
| glycinergic amacrine cell | 3 studies | 23% ± 5% | |
| retina horizontal cell | 3 studies | 21% ± 7% | |
| endothelial cell of vascular tree | 3 studies | 31% ± 16% | |
| hepatocyte | 3 studies | 52% ± 22% | |
| abnormal cell | 3 studies | 31% ± 17% | |
| ependymal cell | 3 studies | 32% ± 18% | |
| B cell | 3 studies | 24% ± 5% | |
| alveolar macrophage | 3 studies | 35% ± 10% | |
| natural killer cell | 3 studies | 24% ± 5% | |
| respiratory goblet cell | 3 studies | 32% ± 11% | |
| goblet cell | 3 studies | 36% ± 22% | |
| transit amplifying cell | 3 studies | 41% ± 28% | |
| mural cell | 3 studies | 31% ± 13% | |
| mucus secreting cell | 3 studies | 31% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 5455.70 | 1445 / 1445 | 100% | 49.29 | 183 / 183 |
| ovary | 100% | 3977.83 | 180 / 180 | 100% | 30.06 | 430 / 430 |
| stomach | 100% | 4026.87 | 359 / 359 | 100% | 41.08 | 286 / 286 |
| lung | 100% | 4057.84 | 578 / 578 | 100% | 42.28 | 1154 / 1155 |
| intestine | 100% | 5098.43 | 966 / 966 | 100% | 42.07 | 526 / 527 |
| breast | 100% | 4653.30 | 459 / 459 | 100% | 47.20 | 1115 / 1118 |
| bladder | 100% | 5115.19 | 21 / 21 | 99% | 37.36 | 501 / 504 |
| prostate | 100% | 3944.22 | 245 / 245 | 99% | 36.99 | 499 / 502 |
| uterus | 100% | 4675.88 | 170 / 170 | 99% | 34.89 | 455 / 459 |
| skin | 100% | 6090.38 | 1809 / 1809 | 99% | 47.70 | 466 / 472 |
| pancreas | 100% | 2831.79 | 327 / 328 | 99% | 33.65 | 176 / 178 |
| kidney | 100% | 3276.19 | 89 / 89 | 99% | 30.70 | 888 / 901 |
| brain | 99% | 3158.64 | 2612 / 2642 | 99% | 27.79 | 701 / 705 |
| thymus | 100% | 3321.33 | 652 / 653 | 98% | 23.03 | 594 / 605 |
| liver | 100% | 3168.38 | 226 / 226 | 96% | 21.30 | 389 / 406 |
| adrenal gland | 100% | 4408.64 | 258 / 258 | 93% | 19.75 | 215 / 230 |
| adipose | 100% | 5015.03 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 5145.98 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 100% | 7363.09 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 3793.82 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 6.54 | 1 / 1 |
| heart | 98% | 3705.42 | 842 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 98% | 36.93 | 44 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 24.41 | 28 / 29 |
| eye | 0% | 0 | 0 / 0 | 86% | 14.17 | 69 / 80 |
| peripheral blood | 72% | 2273.12 | 670 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
| GO_0070936 | Biological process | protein K48-linked ubiquitination |
| GO_0035519 | Biological process | protein K29-linked ubiquitination |
| GO_0000209 | Biological process | protein polyubiquitination |
| GO_0000502 | Cellular component | proteasome complex |
| GO_0061630 | Molecular function | ubiquitin protein ligase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | UBE3C |
| Protein name | Ubiquitin-protein ligase E3C (EC 2.3.2.26) (HECT-type ubiquitin transferase E3C) (Homologous to E6AP carboxyl terminus homologous protein 2) (HectH2) (RTA-associated ubiquitin ligase) (RAUL) Ubiquitin protein ligase E3C |
| Synonyms | KIAA10 KIAA0010 |
| Description | FUNCTION: E3 ubiquitin-protein ligase that specifically catalyzes 'Lys-29'- and 'Lys-48'-linked polyubiquitin chains . Accepts ubiquitin from the E2 ubiquitin-conjugating enzyme UBE2D1 in the form of a thioester and then directly transfers the ubiquitin to targeted substrates . Associates with the proteasome and promotes elongation of ubiquitin chains on substrates bound to the 26S proteasome . Also catalyzes 'Lys-29'- and 'Lys-48'-linked ubiquitination of 26S proteasome subunit ADRM1/RPN13 in response to proteotoxic stress, impairing the ability of the proteasome to bind and degrade ubiquitin-conjugated proteins . Acts as a negative regulator of autophagy by mediating 'Lys-29'- and 'Lys-48'-linked ubiquitination of PIK3C3/VPS34, promoting its degradation . Can assemble unanchored poly-ubiquitin chains in either 'Lys-29'- or 'Lys-48'-linked polyubiquitin chains; with some preference for 'Lys-48' linkages . Acts as a negative regulator of type I interferon by mediating 'Lys-48'-linked ubiquitination of IRF3 and IRF7, leading to their degradation by the proteasome . Catalyzes ubiquitination and degradation of CAND2 . . |
| Accessions | ENST00000348165.10 [Q15386-1] H7C0Y1 ENST00000389103.4 [Q15386-3] Q15386 ENST00000430750.1 |